It is known that several microRNAs (miRNAs) have an important regulatory role during the different stages of atheroma plaque formation. In preclinical studies, the regulation of its expression has been shown beneficial outputs in the treatment of atherosclerosis. Thus, the therapeutic targeting of miRNAs represents an attractive approach for the treatment of atherosclerosis in preclinical and clinical studies. Different approaches have been undertaken to decipher the potential of miRNA therapeutics. To repress pathological miRNAs or over-express protective miRNAs, miRNA inhibitors or miRNA mimics, respectively, have been employed. Despite significant achievements in the field, cellular uptake, the potential need for multiple doses to achieve the desired effect, biodistribution, the ability to target a specific tissue or cell, the unpredictable and unwanted side effects and toxicity still remain the major limitations for miRNA-targeting therapies. All of these challenges have emphasized the need to develop more efficient delivery systems for miRNA therapeutics in the context of atherosclerosis. Thanks to the development of nanotechnology in the molecular biology field, novel delivery miRNA-base therapies have emerged. The use of an innovative therapeutic approach for targeting miRNAs in vivo using a pH Low-Insertion Peptide it might be of interest. Moreover, the incorporation of miRNA into rHDL with therapeutic purposes is promising. Thus, a miR-rHDL could be an innovative technique and a powerful vehicle tool for searching overexpression or inhibition of key miRNAs in atherosclerotic plaques.
Audience Take Away Notes:
- The audience will learn the novelties in the field of miRNAs-base therapies in atherosclerosis